kringle-pharmaCo., Ltd.

NEWS

notice

Mar 11, 2015 Notice

Kringle Pharma completed Phase I clinical trial of recombinant human HGF for amyotrophic lateral sclerosis (ALS). Primary objectives of the trial, the safety and pharmacokinetics of the HGF dosing, were successfully evaluated.

Kringle Pharma completed Phase I clinical trial of recombinant human HGF for amyotrophic lateral sclerosis (ALS). Primary objectives of the trial, the safety and pharmacokinetics of the HGF dosing, were successfully evaluated.